References

References1. Gershon A. Unproven therapies don’t belong in Lyme disease guidelines. South Med J 2009;102:1088.GershonAUnproven therapies don’t belong in Lyme disease guidelines.South Med J200910210882. Connecticut Attorney General’s Office. Attorney General’s investigation reveals flawed Lyme disease guideline process, IDSA agrees to reassess guidelines, install independent arbiter. Available at: http://www.ct.gov/AG/cwp/view.asp?a=2795&q=414284. Accessed May 1, 2008.3. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;41:1089–1134.WormserGP]]DattwylerRJ]]ShapiroED&etal;The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.Clin Infect Dis2006411089-11344. Halperin JJ, Golightly M. Lyme borreliosis in Bell’s palsy. Long Island Neuroborreliosis Collaborative Study Group. Neurology 1992;42:1268–1270.HalperinJJ]]GolightlyMLyme borreliosis in Bell’s palsy. Long Island Neuroborreliosis Collaborative Study Group.Neurology1992421268-12705. Stiernstedt G, Gustafsson R, Karlsson M, et al. Clinical manifestations and diagnosis of neuroborreliosis. Ann N Y Acad Sci 1988;539:46–55.StiernstedtG]]GustafssonR]]KarlssonM&etal;Clinical manifestations and diagnosis of neuroborreliosis.Ann N Y Acad Sci198853946-556. Sigal LH. Early disseminated Lyme disease: cardiac manifestations. Am J Med 1995;98:25S–28S.SigalLHEarly disseminated Lyme disease: cardiac manifestations.Am J Med19959825S-28S7. Embers ME, Ramamoorthy R, Philipp MT. Survival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease. Microbes Infect 2004;6:312–318.EmbersME]]RamamoorthyR]]PhilippMTSurvival strategies of Borrelia burgdorferi, the etiologic agent of Lyme disease.Microbes Infect20046312-3188. Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin Infect Dis 2007;45:149–157.StrickerRBCounterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease.Clin Infect Dis200745149-1579. Cameron DJ. Generalizability in two clinical trials of Lyme disease. Epidemiol Perspect Innov 2006;3:12–18.CameronDJGeneralizability in two clinical trials of Lyme disease.Epidemiol Perspect Innov2006312-1810. Cameron DJ. Insufficient evidence to deny antibiotic treatment to chronic Lyme disease patients. Med Hypotheses 2009;72:688–691.CameronDJInsufficient evidence to deny antibiotic treatment to chronic Lyme disease patients.Med Hypotheses200972688-69111. Stricker RB, Johnson L. The Infectious Diseases Society of America Lyme guidelines: poster child for guidelines reform. South Med J 2009;102:565–566.StrickerRB]]JohnsonLThe Infectious Diseases Society of America Lyme guidelines: poster child for guidelines reform.South Med J2009102565-56612. Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA 2009;301:429–431.SnidermanAD]]FurbergCDWhy guideline-making requires reform.JAMA2009301429-43113. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831–841.TricociP]]AllenJM]]KramerJM&etal;Scientific evidence underlying the ACC/AHA clinical practice guidelines.JAMA2009301831-84114. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA 2009;301:868–869.ShaneyfeltTM]]CentorRMReassessment of clinical practice guidelines: go gently into that good night.JAMA2009301868-869